메뉴 건너뛰기
Annals of the Rheumatic Diseases
Volumn 66, Issue 6, 2007, Pages 835-
Rheumatoid arthritis in Dubai - Delayed diagnosis and low usage of disease modifying antirheumatic drugs [1]
Author keywords

[No Author keywords available]
Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;
EID: 34249776347     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.068171     Document Type: Letter
Times cited : (9)
References (8)
  • 1
    • 0344305693 scopus 로고    scopus 로고
    • The expression of rheumatoid arthritis in Kuwaiti patients in an outpatient hospital-based practice
    • Al-Salem IH, Al-Awadhi AM. The expression of rheumatoid arthritis in Kuwaiti patients in an outpatient hospital-based practice. Med Princ Pract 2004;13:47-50.
    • (2004) Med Princ Pract , vol.13 , pp. 47-50
    • Al-Salem, I.H.1    Al-Awadhi, A.M.2
  • 2
    • 0027724484 scopus 로고
    • Rheumatoid arthritis in a population sample in the Gulf: Clinical observations
    • al Attia HM, Gatee OB, George S, Masri MM. Rheumatoid arthritis in a population sample in the Gulf: clinical observations. Clin Rheumatol 1993;12:506-10.
    • (1993) Clin Rheumatol , vol.12 , pp. 506-510
    • al Attia, H.M.1    Gatee, O.B.2    George, S.3    Masri, M.M.4
  • 4
    • 0028811664 scopus 로고
    • The expression of rheumatoid arthritis in Saudi Arabia
    • Alballa SR. The expression of rheumatoid arthritis in Saudi Arabia. Clin Rheumatol 1995;14:641-5.
    • (1995) Clin Rheumatol , vol.14 , pp. 641-645
    • Alballa, S.R.1
  • 5
    • 34249778321 scopus 로고    scopus 로고
    • Michaud K, Wolfe F. Trends in medication use by 10,982 rheumatoid arthritis patients in the United States from 1998-2005: biological use now at 40%, Ann Rheum Dis 2006;65(Suppl II):311.
    • Michaud K, Wolfe F. Trends in medication use by 10,982 rheumatoid arthritis patients in the United States from 1998-2005: biological use now at 40%, Ann Rheum Dis 2006;65(Suppl II):311.
  • 6
    • 16444377894 scopus 로고    scopus 로고
    • Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis
    • Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005;65:661-94.
    • (2005) Drugs , vol.65 , pp. 661-694
    • Nurmohamed, M.T.1    Dijkmans, B.A.2
  • 7
    • 0038681584 scopus 로고    scopus 로고
    • Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year
    • Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, Borg EJ, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48:1797-807.
    • (2003) Arthritis Rheum , vol.48 , pp. 1797-1807
    • Verstappen, S.M.1    Jacobs, J.W.2    Bijlsma, J.W.3    Heurkens, A.H.4    van Booma-Frankfort, C.5    Borg, E.J.6
  • 8
    • 0034082253 scopus 로고    scopus 로고
    • Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
    • Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
    • (2000) Arthritis Rheum , vol.43 , pp. 22-29
    • Anderson, J.J.1    Wells, G.2    Verhoeven, A.C.3    Felson, D.T.4

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.